N@N

CELGENE CORP (NASDAQ:CELG), Up By 5.76% ($3.38) From $58.670 After BUYINS.NET Report Predicted Strength After Earnings

^{Published on 2011-07-28 07:20:27 - WOPRAI}
 

July 28, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, July 27th 2011 stating that CELGENE CORP (NASDAQ:CELG) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=celg&id=180816

At the time this story was written, CELGENE CORP (NASDAQ:CELG) is Up By 5.76% ($3.38) From $58.670 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

CELGENE CORP (NASDAQ:CELG) - Celgene Corporation discovers, develops, and commercializes innovative therapies to treat cancer and immune-inflammatory diseases in the United States, Europe, and internationally. Its commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as patients with transfusion-dependent anemia; and THALOMID to treat, in combination with dexamethasone, patients with newly diagnosed multiple myeloma, as well as for the prevention and suppression of cutaneous manifestations of erythema nodosum leprosum recurrence. The company also sells VIDAZA, used to subtypes of myelodysplastic syndromes; RITALIN to treat attention deficit hyperactivity disorder; FOCALIN to prevent oncology-related disorders; and ALKERAN to treat multiple myeloma and carcinoma of the ovary. Its development stage products consist of CC-4047, which is in Phase I and Phase II clinical trials for treating disease indications, including sickle cell anemia, myelofibrosis, and multiple myeloma; CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I clinical trial completed product for inflammatory conditions; CC-401, a Phase I clinical trial completed product to identify kinases that regulate pathways critical in inflammation and oncology; CC-930, a Phase Ib clinicial trial completed product for fibrotic conditions; and Amrubicin, a Phase III clinical trial product for small cell lung cancer treatment. In addition, the company is researching stem cells derived from the human placenta, as well as from the umbilical cord. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. and Agios Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. CELGENE CORP (NASDAQ:CELG) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net